Experiences of cancer survivors with chemotherapy-induced peripheral neuropathy in the Netherlands: symptoms, daily limitations, involvement of healthcare professionals, and social support

Abstract Purpose A significant proportion of cancer patients suffer from chemotherapy-induced peripheral neuropathy (CIPN). This descriptive study aimed to examine patients’ experience of CIPN symptoms, daily limitations, involvement of healthcare professionals, and social support. Methods Cross-sectional data have been collected in the Netherlands via a national online questionnaire comprising closed items only (February 2021). Results Out of 3752 respondents, 1975 received chemotherapy only (i.e., without targeted therapy) and were therefore included. The majority (71.2%) reported symptoms i... Mehr ...

Verfasser: van de Graaf, Daniëlle L.
Engelen, Vivian
de Boer, Aize
Vreugdenhil, Gerard
Smeets, Tom
van der Lee, Marije L.
Trompetter, Hester R.
Mols, Floortje
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Reihe/Periodikum: Journal of Cancer Survivorship ; ISSN 1932-2259 1932-2267
Verlag/Hrsg.: Springer Science and Business Media LLC
Schlagwörter: Oncology (nursing) / Oncology
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26849276
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://dx.doi.org/10.1007/s11764-023-01402-4

Abstract Purpose A significant proportion of cancer patients suffer from chemotherapy-induced peripheral neuropathy (CIPN). This descriptive study aimed to examine patients’ experience of CIPN symptoms, daily limitations, involvement of healthcare professionals, and social support. Methods Cross-sectional data have been collected in the Netherlands via a national online questionnaire comprising closed items only (February 2021). Results Out of 3752 respondents, 1975 received chemotherapy only (i.e., without targeted therapy) and were therefore included. The majority (71.2%) reported symptoms in both hands and feet (e.g., tingling and loss of sensation or diminished sensation). Participants reported most limitations in household chores, social activities, hobbies, sports, walking, and sleeping and least in family/(taking care of) children, cycling, driving, self-care, eating and drinking, and sexuality and intimacy. Many patients indicated that their healthcare professionals informed them about the possibility of CIPN development before treatment (58.4%), and they paid attention to CIPN during and after treatment (53.1%). However, many patients (43%) reported a lack of information on what to do when CIPN develops. Few participants (22%) visited their general practitioner (GP) for CIPN. In general, patients’ social environments sometimes to always showed empathy to patients. Conclusions Symptoms of CIPN are frequently reported and can result in various daily limitations. Support from professionals and peers is crucial in managing CIPN, which is sometimes lacking. Appropriate guidance and support should be provided to patients to decrease the impact of CIPN on daily life. Future research should investigate differences in chemotherapeutic agents and the resulting symptoms and consequences.